Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 11/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24077200 | 1.00 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15POLBMEN1 | |
| SCHEMBL25747887 | 0.83 | AKR1B1 (0.42) | AKR1B1NLRP3ALOX15POLBMAPT | |
| SCHEMBL24076315 | 0.82 | ALOX15 (0.64) | AKR1B1NLRP3ALOX15 | |
| SCHEMBL24076971 | 0.82 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15POLBMAPT | |
| SCHEMBL24076912 | 0.82 | AKR1B1 (0.52) | AKR1B1NLRP3ALOX15 | |
| SCHEMBL25746237 | 0.82 | RAB9A (0.53) | AKR1B1ALOX15POLBMEN1KMT2A | |
| SCHEMBL30168567 | 0.81 | NLRP3 (0.64) | AKR1B1NLRP3ALOX15 | |
| SCHEMBL24076327 | 0.81 | NLRP3 (0.64) | AKR1B1NLRP3ALOX15 | |
| SCHEMBL27164166 | 0.81 | AKR1B1 (0.47) | AKR1B1NLRP3ALOX15MAPT | |
| SCHEMBL25747845 | 0.81 | NLRP3 (0.56) | AKR1B1NLRP3ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | AKR1B1 162/4885NLRP3 1/4885ALOX15 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.